7 results on '"Ingenwerth, Marc"'
Search Results
2. Prospective comparison of 18F-FDG PET/MRI and 18F-FDG PET/CT for thoracic staging of non-small cell lung cancer
- Author
-
Kirchner, Julian, Sawicki, Lino M., Nensa, Felix, Schaarschmidt, Benedikt M., Reis, Henning, Ingenwerth, Marc, Bogner, Simon, Aigner, Clemens, Buchbender, Christian, Umutlu, Lale, Antoch, Gerald, Herrmann, Ken, and Heusch, Philipp
- Published
- 2019
- Full Text
- View/download PDF
3. Local and whole-body staging in patients with primary breast cancer: a comparison of one-step to two-step staging utilizing 18F-FDG-PET/MRI
- Author
-
Kirchner, Julian, Grueneisen, Johannes, Martin, Ole, Oehmigen, Mark, Quick, Harald H., Bittner, Ann-Kathrin, Hoffmann, Oliver, Ingenwerth, Marc, Catalano, Onofrio Antonio, Heusch, Philipp, Buchbender, Christian, Forsting, Michael, Antoch, Gerald, Herrmann, Ken, and Umutlu, Lale
- Published
- 2018
- Full Text
- View/download PDF
4. Prospective evaluation of whole-body MRI and 18F-FDG PET/MRI in N and M staging of primary breast cancer patients.
- Author
-
Bruckmann, Nils Martin, Sawicki, Lino M., Kirchner, Julian, Martin, Ole, Umutlu, Lale, Herrmann, Ken, Fendler, Wolfgang, Bittner, Ann-Kathrin, Hoffmann, Oliver, Mohrmann, Svjetlana, Dietzel, Frederic, Ingenwerth, Marc, Schaarschmidt, Benedikt M., Li, Yan, Kowall, Bernd, Stang, Andreas, Antoch, Gerald, and Buchbender, Christian
- Subjects
MAGNETIC resonance mammography ,BREAST cancer ,CANCER patients ,TUMOR classification ,LYMPH nodes ,DIAGNOSTIC imaging - Abstract
Objectives: To evaluate and compare the diagnostic potential of whole-body MRI and whole-body
18 F-FDG PET/MRI for N and M staging in newly diagnosed, histopathologically proven breast cancer. Material and methods: A total of 104 patients (age 53.4 ± 12.5) with newly diagnosed, histopathologically proven breast cancer were enrolled in this study prospectively. All patients underwent a whole-body18 F-FDG PET/MRI. MRI and18 F-FDG PET/MRI datasets were evaluated separately regarding lesion count, lesion localization, and lesion characterization (malignant/benign) as well as the diagnostic confidence (5-point ordinal scale, 1–5). The N and M stages were assessed according to the eighth edition of the American Joint Committee on Cancer staging manual in MRI datasets alone and in18 F-FDG PET/MRI datasets, respectively. In the majority of lesions histopathology served as the reference standard. The remaining lesions were followed-up by imaging and clinical examination. Separately for nodal-positive and nodal-negative women, a McNemar chi2 test was performed to compare sensitivity and specificity of the N and M stages between18 F-FDG PET/MRI and MRI. Differences in diagnostic confidence scores were assessed by Wilcoxon signed rank test. Results: MRI determined the N stage correctly in 78 of 104 (75%) patients with a sensitivity of 62.3% (95% CI: 0.48–0.75), a specificity of 88.2% (95% CI: 0.76–0.96), a PPV (positive predictive value) of 84.6% % (95% CI: 69.5–0.94), and a NPV (negative predictive value) of 69.2% (95% CI: 0.57–0.8). Corresponding results for18 F-FDG PET/MRI were 87/104 (83.7%), 75.5% (95% CI: 0.62–0.86), 92.2% (0.81–0.98), 90% (0.78–0.97), and 78.3% (0.66–0.88), showing a significantly better sensitivity of18 F-FDG PET/MRI determining malignant lymph nodes (p = 0.008). The M stage was identified correctly in MRI and18 F-FDG PET/MRI in 100 of 104 patients (96.2%). Both modalities correctly staged all 7 patients with distant metastases, leading to false-positive findings in 4 patients in each modality (3.8%). In a lesion-based analysis,18 F-FDG PET/MRI showed a significantly better performance in correctly determining malignant lesions (85.8% vs. 67.1%, difference 18.7% (95% CI: 0.13–0.26), p < 0.0001) and offered a superior diagnostic confidence compared with MRI alone (4.1 ± 0.7 vs. 3.4 ± 0.7, p < 0.0001). Conclusion:18 F-FDG PET/MRI has a better diagnostic accuracy for N staging in primary breast cancer patients and provides a significantly higher diagnostic confidence in lesion characterization than MRI alone. But both modalities bear the risk to overestimate the M stage. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
5. Prospective comparison of 18F-FDG PET/MRI and 18F-FDG PET/CT for thoracic staging of non-small cell lung cancer.
- Author
-
Kirchner, Julian, Sawicki, Lino M., Schaarschmidt, Benedikt M., Buchbender, Christian, Antoch, Gerald, Heusch, Philipp, Nensa, Felix, Umutlu, Lale, Reis, Henning, Ingenwerth, Marc, Bogner, Simon, Aigner, Clemens, and Herrmann, Ken
- Subjects
NON-small-cell lung carcinoma ,POSITRON emission ,MAGNETIC resonance imaging ,FLUORODEOXYGLUCOSE F18 ,TUMOR classification ,LYMPH node diseases - Abstract
Objectives: To compare the diagnostic performance of
18 F-FDG PET/MRI and18 F-FDG PET/CT for primary and locoregional lymph node staging in non-small cell lung cancer (NSCLC).Methods: In this prospective study, a total of 84 patients (51 men, 33 women, mean age 62.5 ± 9.1 years) with histopathologically confirmed NSCLC underwent18 F-FDG PET/CT followed by18 F-FDG PET/MRI in a single injection protocol. Two readers independently assessed T and N staging in separate sessions according to the seventh edition of the American Joint Committee on Cancer staging manual for18 F-FDG PET/CT and18 F-FDG PET/MRI, respectively. Histopathology as a reference standard was available for N staging in all 84 patients and for T staging in 39 patients. Differences in staging accuracy were assessed by McNemars chi2 test. The maximum standardized uptake value (SUVmax ) and longitudinal diameters of primary tumors were correlated using Pearson's coefficients.Results: T stage was categorized concordantly in18 F-FDG PET/MRI and18 F-FDG PET/CT in 38 of 39 (97.4%) patients. Herein,18 F-FDG PET/CT and18 F-FDG PET/MRI correctly determined the T stage in 92.3 and 89.7% of patients, respectively. N stage was categorized concordantly in 83 of 84 patients (98.8%).18 F-FDG PET/CT correctly determined the N stage in 78 of 84 patients (92.9%), while18 F-FDG PET/MRI correctly determined the N stage in 77 of 84 patients (91.7%). Differences between18 F-FDG PET/CT and18 F-FDG PET/MRI in T and N staging accuracy were not statistically significant (p > 0.5, each). Tumor size and SUVmax measurements derived from both imaging modalities exhibited excellent correlation (r = 0.963 and r = 0.901, respectively).Conclusion:18 F-FDG PET/MRI and18 F-FDG PET/CT show an equivalently high diagnostic performance for T and N staging in patients suffering from NSCLC. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
6. Local and whole-body staging in patients with primary breast cancer: a comparison of one-step to two-step staging utilizing 18F-FDG-PET/MRI.
- Author
-
Kirchner, Julian, Martin, Ole, Heusch, Philipp, Buchbender, Christian, Antoch, Gerald, Grueneisen, Johannes, Forsting, Michael, Umutlu, Lale, Oehmigen, Mark, Quick, Harald H., Bittner, Ann-Kathrin, Hoffmann, Oliver, Ingenwerth, Marc, Catalano, Onofrio Antonio, and Herrmann, Ken
- Subjects
BREAST cancer ,TUMOR classification ,FLUORODEOXYGLUCOSE F18 ,POSITRON emission ,HISTOPATHOLOGY - Abstract
Objectives: The purpose of this study was to compare the diagnostic value of a one-step to a two-step staging algorithm utilizing
18 F-FDG PET/MRI in breast cancer patients.Methods: A total of 38 patients (37 females and one male, mean age 57 ± 10 years; range 31-78 years) with newly diagnosed, histopathologically proven breast cancer were prospectively enrolled in this trial. All PET/MRI examinations were assessed for local tumor burden and metastatic spread in two separate reading sessions: (1) One-step algorithm comprising supine whole-body18 F-FDG PET/MRI, and (2) Two-step algorithm comprising a dedicated prone18 F-FDG breast PET/MRI and supine whole-body18 F-FDG PET/MRI.Results: On a patient based analysis the two-step algorithm correctly identified 37 out of 38 patients with breast carcinoma (97%), while five patients were missed by the one-step18 F-FDG PET/MRI algorithm (33/38; 87% correct identification). On a lesion-based analysis 56 breast cancer lesions were detected in the two-step algorithm and 44 breast cancer lesions could be correctly identified in the one-step18 F-FDG PET/MRI (79%), resulting in statistically significant differences between the two algorithms (p = 0.0015). For axillary lymph node evaluation sensitivity, specificity and accuracy was 93%, 95 and 94%, respectively. Furthermore, distant metastases could be detected in seven patients in both algorithms.Conclusion: The results demonstrate the necessity and superiority of a two-step18 F-FDG PET/MRI algorithm, comprising dedicated prone breast imaging and supine whole-body imaging, when compared to the one-step algorithm for local and whole-body staging in breast cancer patients. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
7. Correlation between contrast enhancement, standardized uptake value (SUV), and diffusion restriction (ADC) with tumor grading in patients with therapy-naive neuroendocrine neoplasms using hybrid 68Ga-DOTATOC PET/MRI.
- Author
-
Bruckmann, Nils Martin, Rischpler, Christoph, Kirchner, Julian, Umutlu, Lale, Herrmann, Ken, Ingenwerth, Marc, Theurer, Sarah, Lahner, Harald, Antoch, Gerald, and Sawicki, Lino M.
- Subjects
- *
TUMOR grading , *MAGNETIC resonance imaging , *LOGISTIC regression analysis , *PEARSON correlation (Statistics) , *TUMORS , *RADIOISOTOPES , *OCTREOTIDE acetate , *GALLIUM isotopes , *DIAGNOSTIC imaging , *RADIOPHARMACEUTICALS , *DEOXY sugars , *LONGITUDINAL method - Abstract
Objectives: To investigate a correlation between 68Ga-DOTATOC PET/MR imaging parameters such as arterial and venous contrast enhancement, diffusion restriction, and maximum standardized uptake value (SUVmax) with histopathological tumor grading in patients with neuroendocrine neoplasms (NEN).Material and Methods: A total of 26 patients with newly diagnosed, therapy-naive neuroendocrine neoplasms (NEN) were enrolled in this prospective study and underwent 68Ga-DOTATOC PET/MRI. Images were evaluated regarding NEN lesion number and location, predominant tumor signal intensity on precontrast T1w and T2w images and on postcontrast arterial and portal venous phase T1w images, apparent diffusion coefficient (ADC) and SUVmax. Histopathological tumor grading was assessed and related to PET/MRI features using Pearson's correlation coefficient and Fisher's exact t-test. A binary logistic regression analysis was performed to evaluate a potential relation with an aggressive tumor biology and odds ratios (OR) were calculated.Results: There was a moderate negative correlation between arterial contrast enhancement and tumor grading (r=-0.35, p = 0.005), while portal venous enhancement showed a weak positive correlation with the Ki-67 index (r = 0.28, p = 0.008) and a non-significant positive correlation with tumor grading (r = 0.19, p = 0.063). Features that were significantly associated with an aggressive tumor biology were the presence of liver metastases (OR 2.6, p = 0.042), T1w hyperintensity in comparison to muscle (OR 12.7, p = 0.0001), arterial phase hyperenhancement (OR 1.4, p = 0.001), diffusion restriction (OR 2.8, p = 0.02) and SUVmax above the hepatic level (OR 7.0, p = 0.001).Conclusion: The study reveals that PET/MRI features might be useful for prediction of NEN grading and thus provide a preliminary assessment of tumor aggressiveness. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.